One enzyme, two changes, one rising level: a metabolism review from MN660's sixth unit traces clozapine through CYP1A2 after a composite patient quits smoking, then after [fluvoxamine] is added. Searches like "mn 660 unit 6 assignment example", "mn660 unit 6 sample" and "mn660 unit 6 example" land here.
What a finished MN660 Unit 6 metabolism and interaction review looks like
A pathway diagram and five paragraphs. The diagram shows clozapine cleared mainly by hepatic CYP1A2, with smaller contributions from CYP3A4 and CYP2C19, to norclozapine and clozapine N-oxide. Paragraph one explains induction: polycyclic aromatic hydrocarbons in tobacco smoke activate the aryl hydrocarbon receptor, which raises CYP1A2 expression, so smokers clear clozapine faster. Paragraph two runs the process in reverse when he stops: induction fades as the enzyme turns over, clearance falls, and plasma clozapine rises substantially across roughly the following week or two. Paragraph three notes that nicotine replacement does not restore induction, because nicotine is not the inducer. Paragraph four covers a second scenario in which [fluvoxamine] is added, a strong CYP1A2 inhibitor that can multiply clozapine exposure. Paragraph five lists what rising levels would be expected to produce: sedation, hypersalivation, orthostasis and a lowered seizure threshold.
How a MN660 Unit 6 example is structured
The case is given in four lines at the top, including the one detail that drives everything, his smoking history, and the regimen itself appears only as [clozapine, established dose] in brackets. Each interaction is then written in a fixed sequence: the enzyme, the direction of change in its activity, the direction of change in the drug's concentration, the approximate time course, and the observable consequence. That sequence answers the question this unit commonly poses before anyone can ask it. The smoking section precedes the fluvoxamine section because de-induction is the less intuitive of the two and the one most often missed. A short paragraph on caffeine, another CYP1A2 substrate, shows the same enzyme raising a second level in the same man. The conclusion notes that therapeutic drug monitoring exists partly for this reason and leaves any action to the prescriber. Label and review citations follow.
One detail in the case matters most
His smoking history sits in the first line of the case summary. Everything the review goes on to explain follows from that single fact, and placing it first stops a reader from treating it as background.
Direction before magnitude
For each interaction the review states whether enzyme activity rises or falls and which plasma level moves as a result, before any estimate of size. A reader who retains nothing else still leaves with the correct direction.
Why the patch does not help
Nicotine replacement leaves induction unrestored because the hydrocarbons in smoke, not nicotine, switch on CYP1A2. A full paragraph goes to this point, the misunderstanding met most often in the whole interaction.
An inhibitor for contrast
The fluvoxamine scenario shows the same enzyme blocked rather than released from induction. Placed next to each other, the two scenarios make the review about CYP1A2 as a mechanism instead of one memorized pair of drugs.
A second level rising quietly
Caffeine, also cleared by CYP1A2, climbs after cessation as well. The review mentions it because restlessness from coffee he has always drunk could be misread as a change in his psychiatric condition.
Where marks go in MN660 Unit 6
Deductions in this review fall first on an interaction named with no direction, a sentence saying smoking affects clozapine that gives no hint which way the level moves. Close to that in cost is naming the wrong enzyme, usually CYP3A4 or CYP2D6, as the main route. Graders also mark down the belief that nicotine is the inducer, which leads to the wrong conclusion about replacement therapy. A review that gives the direction but no time course misses why the risk concentrates in the days after cessation. Any sentence prescribing a new amount, or telling a reader how to adjust one, is treated as outside the assignment, since the task is to predict the concentration rather than to manage it. Minor losses come from caffeine left out and from diagrams with arrows but no enzyme labels.
Get a MN660 Unit 6 example written to your instructions
Does your Unit 6 prompt supply the drug pair, or ask you to choose an interaction? Either suits this format. Include the case, the rubric and any required layout. The first review is free, written to those instructions and returned in 24-48h, with every interaction stated as enzyme, direction, concentration, timing and effect, and any regimen bracketed as a composite.
MN660 Unit 6 questions, answered
Should the review include specific plasma level targets?
Only as reported ranges from a cited source, and only if the prompt asks. Clozapine monitoring uses published reference ranges, and a review can note that such ranges exist and why they matter here. Advising what level a particular patient should reach, or how to adjust toward it, moves from pharmacology into management and is best left out.
How do I decide which enzyme is the main route?
Check the product label and a pharmacology reference, which usually state the primary and minor pathways. For clozapine, CYP1A2 is the major route, with lesser roles for CYP3A4 and CYP2C19. When references disagree about minor pathways, cite the one you used and focus the review on the pathway that carries the interaction you are explaining.
Is it enough to say a drug is an inhibitor?
Rarely. Say which enzyme it inhibits, how strongly by the usual classification, and which substrate level rises as a result. Naming an inhibitor but not its enzyme leaves the reader unable to predict anything, and that gap is among the most common reasons metabolism work in this course loses marks.